^
Association details:
| Biomarker: | EGFR wild-type + ALK wild-type + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
Published date:
06/07/2023
Excerpt:
PEOPLE (NCT03447678) was a prospective phase II trial evaluating first-line pembrolizumab in patients with advanced EGFR and ALK wild type treatment-naïve NSCLC with PD-L1 <50%....The median PFS was 2.9 mo (95% CI 1.8 to 5.8) and the median OS was 12.1 mo (95% CI 9.0 to 20.2)....The ORR was 24.1%, DCR was 53.4% and the median DoR was 14.5 mo (95% CI 8.4 to 24.9).
DOI:
10.1136/jitc-2023-006833
Trial ID:
